Recently, we found another selective vulnerability of these KL co-mutant cancers to inhibition of glutamine-fructose-6-phosphate transaminase 2 (GFPT2), a rate-limiting enzyme in the amino sugar/nucleotide sugar pathway called the hexosamine biosynthesis pathway (HBP) [13]. This evidence concerns the gene GFPT2 and cancer.